GM
GM0N.F Globus Medical Inc
- Market cap
- EUR 8.89B
- P/E
- 19.2x
- P/B
- 2.07x
- ROE
- 11.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GM0N.F undervalued?
Graham numberGM0N.F trades 32.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Globus Medical Inc fundamental analysis
No fundamental analysis for Globus Medical Inc yet.
Globus Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Globus Medical Inc
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction …
Full company profileGlobus Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Globus Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 564M | 636M | 713M | 785M | 789M | 958M | 1.02B | 1.57B | 2.52B | 2.94B | 3.08B |
| Gross Profit | 429M | 486M | 554M | 605M | 572M | 719M | 759M | 1.02B | 1.48B | 1.98B | 2.14B |
| Operating Income | 159M | 166M | 177M | 177M | 115M | 195M | 236M | 201M | 219M | 537M | 714M |
| EBITDA | - | 205M | 217M | 225M | 178M | 265M | 305M | 347M | 473M | 814M | 994M |
| Net Income | 104M | 107M | 156M | 155M | 102M | 149M | 190M | 123M | 103M | 538M | 556M |
| EPS | - | 1.11 | 1.59 | 1.55 | 1.03 | 1.47 | 1.90 | 0.90 | 0.75 | 3.98 | 4.19 |
| Balance Sheet | |||||||||||
| Total Assets | 928M | 1.08B | 1.30B | 1.53B | 1.68B | 1.96B | 2.08B | 5.09B | 5.25B | 5.30B | 5.53B |
| Total Liabilities | 95.6M | 111M | 115M | 130M | 173M | 216M | 230M | 1.09B | 1.07B | 730M | 732M |
| Shareholders' Equity | 832M | 968M | 1.19B | 1.40B | 1.51B | 1.74B | 1.85B | 4.00B | 4.18B | 4.57B | 4.80B |
| Cash & Short-term Investments | 133M | 119M | 140M | 195M | 239M | 193M | 150M | 467M | 784M | 526M | 441M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 148M | 159M | 182M | 172M | 199M | 276M | 178M | 243M | 521M | 753M | 903M |
| Capital Expenditure | 40.9M | 51.3M | 59.7M | 70.8M | 63.7M | 56.9M | 74.0M | 78.3M | 115M | 174M | 151M |
| Free Cash Flow | - | 108M | 122M | 101M | 135M | 219M | 104M | 165M | 405M | 579M | 752M |
| Ratios | |||||||||||
| ROE | 12.5% | 11.1% | 13.2% | 11.1% | 6.8% | 8.6% | 10.3% | 3.1% | 2.5% | 11.8% | 11.6% |
| ROA | 11.2% | 10.0% | 12.0% | 10.1% | 6.1% | 7.6% | 9.2% | 2.4% | 2.0% | 10.1% | 10.1% |
| Net Profit Margin | 18.5% | 16.9% | 21.9% | 19.8% | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% | 18.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Globus Medical Inc dividends
Globus Medical Inc has not paid dividends in the last 9 fiscal years.
Who owns Globus Medical Inc
- Insiders 0.75%
- Institutions 99.25%
- Public & others 0.00%
- Shares outstanding 110M
- Free float 109M
Globus Medical Inc company profile
- Company name
- Globus Medical Inc
- Ticker
- GM0N.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6,000
- Fiscal year end
- December
- Address
- 2560 General Armistead Avenue, Audubon, PA, United States, 19403-5214
- Phone
- 610 930 1800
- Website
- globusmedical.com
About Globus Medical Inc
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Globus Medical Inc management
5- Mr. David C. PaulCo-Founder & Executive Chairman · born 1967
- Mr. Keith W. PfeilCEO, President & Director · born 1979
- Mr. Kyle R. KlinSenior VP & CFO · born 1986
- Ms. Kelly G. Huller Esq.Executive VP, General Counsel & Corporate Secretary · born 1972
- Mr. Brian J. KearnsSenior Vice President of Business Development & Investor Relations · born 1967